Precision Medicine News and Research

RSS

Consumer Genetics Conference to take place from October 3-5

Advancements in sequencing and diagnostics technology are the underlying elements driving the genomic revolution. With the free-falling cost of sequencing, richer reference data and improved interpretation methods, the use of personal genomics is beginning to take greater root in clinical practice.

15 Sep 2012

Four new studies on the treatment of early breast cancer

Four new studies on the treatment of early breast cancer, spanning from diagnosis through surgery, were released today in advance of the 2012 Breast Cancer Symposium.

13 Sep 2012

ICREA researcher updates latest findings in applied epigenetics

The research team led by Manel Esteller, director of the Cancer Epigenetics and Biology Program at the Bellvitge Biomedical Research Institute (IDIBELL), professor of genetics at the University of Barcelona and ICREA researcher, has updated the latest findings in applied epigenetics in a review paper published in Nature Reviews Genetics.

13 Sep 2012

APS conference to explore potential mechanisms behind health benefits of exercise

The effects of physical inactivity are, literally, hazardous to your health. Although the detrimental effects of being inactive are generally thought to be associated with childhood obesity and Type 2 diabetes, they have a significant impact on other illnesses. Physical inactivity contributed at least 25 percent to the prevalence of hip fractures, osteoporosis, coronary heart disease, and colon cancer according to recent data released by the U.S. Department of Health and Human Services.

12 Sep 2012

New model reveals how immune system functions under conditions of neutropenia

Cancer chemotherapy can be a life-saver, but it is fraught with severe side effects, among them an increased risk of infection. Until now, the major criterion for assessing this risk has been the blood cell count: if the number of white blood cells falls below a critical threshold, the risk of infection is thought to be high.

12 Sep 2012

Automated system for mapping protein-DNA interactions

Since the sequencing of the human genome in 2001, all our genes - around 20,000 in total - have been identified. But much is still unknown - for instance where and when each is active. Next to each gene sits a short DNA segment, and the activity of this regulatory segment determines whether the gene will be turned on, where and how strongly.

10 Sep 2012

Genetic test to help prescribe proper dose of blood-thinner warfarin

Patients suffering from dangerous blood clots will receive genetic testing to help health professionals at the University of Illinois Hospital & Health Sciences System prescribe the proper dose of the blood-thinner warfarin.

7 Sep 2012

Molecular ‘timetable’ could aid personalized medicine

Researchers have developed a method, based on analysis of circadian rhythm metabolites in blood samples, which can pinpoint the time of the body’s internal “clock” to within 3 hours.

4 Sep 2012

Veterans Affairs San Diego Healthcare System initiates Pathway Fit clinical trial in obesity

Pathway Genomics Corporation, a San Diego-based genetic testing laboratory, has announced a clinical trial with the Veterans Affairs San Diego Healthcare System (VASDHS).

1 Sep 2012

SureGene selects PGXL as laboratory provider for STA2R genetic panel

SureGene has chosen PGXL as laboratory provider for its proprietary STA2R genetic panel, which promises to revolutionize the treatment of schizophrenia.

30 Aug 2012

Mexican-Americans with ancestral links have higher insulin resistance levels

Mexican-Americans with an ancestral link to Amerindian tribes were found to have higher insulin resistance levels, which is an indication of several chronic conditions such as type 2 diabetes, according to research by The University of Texas Health Science Center at Houston (UTHealth).

26 Aug 2012

McGill University experts to present at World Cancer Congress

The following list includes some of the McGill University experts who will be attending or presenting at the World Cancer Congress (WCC), the largest gathering of international leaders in the field of cancer, taking place in Montreal from August 27 to 30, 2012.

24 Aug 2012

Impulsiveness linked to bipolar disorder severity

Trait impulsiveness is associated with a severe course of bipolar disorder, researchers report.

21 Aug 2012

U-M, IGC launch new joint venture for personalized medicine

As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.

17 Aug 2012

Radiosensitivity molecular signature can lead to better radiation therapy decisions for breast cancer

Researchers at Moffitt Cancer Center, working with colleagues in Sweden, the Netherlands and Puerto Rico, have validated a radiosensitivity molecular signature that can lead to better radiation therapy decisions for treating patients with breast cancer.

16 Aug 2012

Thomson Reuters welcomes GenoSpace to Life Sciences Partner Ecosystem

The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced that GenoSpace joined its Life Sciences Partner Ecosystem.

16 Aug 2012

Quintiles acquires premier provider of genomics testing and analysis

To help biopharmaceutical companies dramatically improve drug development productivity and deliver greater value, Quintiles today announced the acquisition of Expression Analysis, Inc. (EA), a premier provider of genomics testing and analysis to biopharma, academic, government and non-profit customers.

13 Aug 2012

Medical ethics: an interview with Anita Silvers

Medical ethics assists healthcare professionals to make decisions respectful of persons who happen to be their patients.

13 Aug 2012

Affymetrix second quarter total revenue increases to $66.4 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2012. Total revenue for the quarter was $66.4 million, including approximately $1.4 million in revenue from eBioscience following the close of Affymetrix's acquisition of the company on June 25. This compares to total revenue of $64.7 million for the same period of 2011.

31 Jul 2012

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

SuppreMol GmbH, an autoimmune disease specialist, today announced a licensing agreement with the University Hospital of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal antibody for early diagnosis and treatment of Rheumatoid Arthritis (RA). SuppreMol will advance preclinical development of SM401 for treatment of RA. Simultaneously, the Company will further validate a highly sensitive human IL-3 diagnostic assay for patient stratification.

24 Jul 2012